What are Allogeneic cell therapy drugs?

Allogeneic cell therapy drugs are pharmacologic agents that share a common mechanism. 1 are currently marketed, with 5 more in clinical development.

What are the marketed Allogeneic cell therapy drugs?

Marketed Allogeneic cell therapy drugs include Allogenix Plus.

1 marketed 3 in Phase 3 2 in Phase 2

This page covers all Allogeneic cell therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds.

Allogenix Plus · University of Missouri-Columbia · Regenerative Medicine
Allogenix Plus is an allogeneic cellular therapy that uses donated human cells to promote tissue regeneration and repair.

JTA-004 · Bone Therapeutics S.A · Orthopedics / Bone Regeneration
JTA-004 is an allogeneic cell therapy derived from bone marrow-derived mesenchymal stem cells that promotes bone regeneration and repair.
NiCord® (omidubicel) · Gamida Cell ltd · Hematology/Oncology
Omidubicel is an ex vivo expanded allogeneic umbilical cord blood-derived hematopoietic progenitor cell product that enhances hematopoietic recovery after transplantation.
Deramiocel (CAP-1002) · Capricor Inc. · Cardiovascular
Deramiocel is an allogeneic cardiosphere-derived cell therapy that promotes cardiac repair and reduces inflammation following myocardial injury.

AVOVA-1 · Aivita Biomedical, Inc. · Regenerative Medicine / Immunology
AVOVA-1 is an allogeneic cell therapy derived from umbilical cord tissue that aims to promote tissue regeneration and reduce inflammation.
CAP-1002 · Capricor Inc. · Cardiovascular
CAP-1002 is an allogeneic cardiosphere-derived cell therapy that promotes cardiac repair and regeneration through paracrine signaling and immunomodulation.